The 5-Year Course of Medication Treatment in Childhood Anxiety Disorders

Stephen Perry Whiteside, Leslie A. Sim, Mark W. Olsen, Melissa K. Hord

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: For pediatric psychiatric disorders, given the marked increase in use of medications without an understanding of the typical treatment course, the primary goal of the current study was to examine the course of pharmacotherapy over 5 years in children with newly diagnosed anxiety disorders. METHODS: We reviewed provider billing and prescription ordering records of a tertiary medical center from 2008 through 2015 to identify children (aged 7-17 years) newly diagnosed with an anxiety disorder and to determine the psychopharmacologic treatment that they received from 2010 through 2015. The frequency at which patients received prescriptions from 9 classes of psychotropic medications at any point during the study period was determined. We used χ² analyses and independent sample t tests to examine the relationship between receiving a psychotropic prescription and various patient characteristics. RESULTS: The study cohort included 108 patients (mean [SD] age = 12.8 [3.3] years). In this group, 73.1% received pharmacotherapy on at least 1 occasion over the 5-year period, and 41.7% received medications from more than 1 class. Of those who received a prescription, 50% (27/54) of patients remained on medication for 5 years. This estimate rose to 71% (5/7) within the subset of patients who were medication-naive at the beginning of the observation period and were still in high school during year 5. CONCLUSIONS: Guidelines implying discontinuation of medication after symptom remission and a limited period of stability do not accurately reflect clinical practice.

Original languageEnglish (US)
JournalThe Journal of clinical psychiatry
Volume80
Issue number3
DOIs
StatePublished - May 14 2019

Fingerprint

Anxiety Disorders
Prescriptions
Therapeutics
Drug Therapy
Psychiatry
Cohort Studies
Observation
Guidelines
Pediatrics

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

The 5-Year Course of Medication Treatment in Childhood Anxiety Disorders. / Whiteside, Stephen Perry; Sim, Leslie A.; Olsen, Mark W.; Hord, Melissa K.

In: The Journal of clinical psychiatry, Vol. 80, No. 3, 14.05.2019.

Research output: Contribution to journalArticle

@article{89c3cdb38e0646cfb7d158686b8b36ff,
title = "The 5-Year Course of Medication Treatment in Childhood Anxiety Disorders",
abstract = "OBJECTIVE: For pediatric psychiatric disorders, given the marked increase in use of medications without an understanding of the typical treatment course, the primary goal of the current study was to examine the course of pharmacotherapy over 5 years in children with newly diagnosed anxiety disorders. METHODS: We reviewed provider billing and prescription ordering records of a tertiary medical center from 2008 through 2015 to identify children (aged 7-17 years) newly diagnosed with an anxiety disorder and to determine the psychopharmacologic treatment that they received from 2010 through 2015. The frequency at which patients received prescriptions from 9 classes of psychotropic medications at any point during the study period was determined. We used χ² analyses and independent sample t tests to examine the relationship between receiving a psychotropic prescription and various patient characteristics. RESULTS: The study cohort included 108 patients (mean [SD] age = 12.8 [3.3] years). In this group, 73.1{\%} received pharmacotherapy on at least 1 occasion over the 5-year period, and 41.7{\%} received medications from more than 1 class. Of those who received a prescription, 50{\%} (27/54) of patients remained on medication for 5 years. This estimate rose to 71{\%} (5/7) within the subset of patients who were medication-naive at the beginning of the observation period and were still in high school during year 5. CONCLUSIONS: Guidelines implying discontinuation of medication after symptom remission and a limited period of stability do not accurately reflect clinical practice.",
author = "Whiteside, {Stephen Perry} and Sim, {Leslie A.} and Olsen, {Mark W.} and Hord, {Melissa K.}",
year = "2019",
month = "5",
day = "14",
doi = "10.4088/JCP.18m12318",
language = "English (US)",
volume = "80",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "3",

}

TY - JOUR

T1 - The 5-Year Course of Medication Treatment in Childhood Anxiety Disorders

AU - Whiteside, Stephen Perry

AU - Sim, Leslie A.

AU - Olsen, Mark W.

AU - Hord, Melissa K.

PY - 2019/5/14

Y1 - 2019/5/14

N2 - OBJECTIVE: For pediatric psychiatric disorders, given the marked increase in use of medications without an understanding of the typical treatment course, the primary goal of the current study was to examine the course of pharmacotherapy over 5 years in children with newly diagnosed anxiety disorders. METHODS: We reviewed provider billing and prescription ordering records of a tertiary medical center from 2008 through 2015 to identify children (aged 7-17 years) newly diagnosed with an anxiety disorder and to determine the psychopharmacologic treatment that they received from 2010 through 2015. The frequency at which patients received prescriptions from 9 classes of psychotropic medications at any point during the study period was determined. We used χ² analyses and independent sample t tests to examine the relationship between receiving a psychotropic prescription and various patient characteristics. RESULTS: The study cohort included 108 patients (mean [SD] age = 12.8 [3.3] years). In this group, 73.1% received pharmacotherapy on at least 1 occasion over the 5-year period, and 41.7% received medications from more than 1 class. Of those who received a prescription, 50% (27/54) of patients remained on medication for 5 years. This estimate rose to 71% (5/7) within the subset of patients who were medication-naive at the beginning of the observation period and were still in high school during year 5. CONCLUSIONS: Guidelines implying discontinuation of medication after symptom remission and a limited period of stability do not accurately reflect clinical practice.

AB - OBJECTIVE: For pediatric psychiatric disorders, given the marked increase in use of medications without an understanding of the typical treatment course, the primary goal of the current study was to examine the course of pharmacotherapy over 5 years in children with newly diagnosed anxiety disorders. METHODS: We reviewed provider billing and prescription ordering records of a tertiary medical center from 2008 through 2015 to identify children (aged 7-17 years) newly diagnosed with an anxiety disorder and to determine the psychopharmacologic treatment that they received from 2010 through 2015. The frequency at which patients received prescriptions from 9 classes of psychotropic medications at any point during the study period was determined. We used χ² analyses and independent sample t tests to examine the relationship between receiving a psychotropic prescription and various patient characteristics. RESULTS: The study cohort included 108 patients (mean [SD] age = 12.8 [3.3] years). In this group, 73.1% received pharmacotherapy on at least 1 occasion over the 5-year period, and 41.7% received medications from more than 1 class. Of those who received a prescription, 50% (27/54) of patients remained on medication for 5 years. This estimate rose to 71% (5/7) within the subset of patients who were medication-naive at the beginning of the observation period and were still in high school during year 5. CONCLUSIONS: Guidelines implying discontinuation of medication after symptom remission and a limited period of stability do not accurately reflect clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=85066845075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066845075&partnerID=8YFLogxK

U2 - 10.4088/JCP.18m12318

DO - 10.4088/JCP.18m12318

M3 - Article

C2 - 31091028

AN - SCOPUS:85066845075

VL - 80

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 3

ER -